GOG-3102 MK-2870-021 Maintenance Tx in HRD-Neg OC

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)
Principal Investigator
Headshot of Jennifer Leah McNally
Associate Professor of Obstetrics and Gynecology
Protocol Number
IRB: PRO00119793
NCT: NCT07318558
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL